La Jolla’s lead drug hits the primary in PhIII, igniting shares as execs hustle to the FDA
Shares of La Jolla Pharmaceutical surged early Monday after the biotech scored a hit on the primary endpoint in its Phase III of LJPC …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
